Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

[1]  J. Wright,et al.  A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia , 2011, Leukemia.

[2]  Suzanne F. Jones,et al.  Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[3]  M. Prados,et al.  Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. , 2011, Neuro-oncology.

[4]  Yumi Kim,et al.  Aurora Kinases and Protein Phosphatase 1 Mediate Chromosome Congression through Regulation of CENP-E , 2010, Cell.

[5]  N. Heisterkamp,et al.  Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias , 2010, Molecular Cancer Therapeutics.

[6]  N. Russell,et al.  The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells , 2010, Molecular Cancer Therapeutics.

[7]  H. Dombret,et al.  Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia . , 2009 .

[8]  Riccardo Spinelli,et al.  Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Suzanne F. Jones,et al.  A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[10]  S. Balabanov,et al.  Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. , 2009, Neoplasia.

[11]  C. Cubitt,et al.  A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias , 2011, Clinical Cancer Research.

[12]  C. Bokemeyer,et al.  Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. , 2008, Blood.

[13]  Paola Storici,et al.  PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer , 2007, Molecular Cancer Therapeutics.

[14]  P. Dent,et al.  Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. , 2007, Blood.

[15]  C. Sawyers,et al.  PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL. , 2007 .

[16]  Jennifer L. Snead,et al.  Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. , 2009, Blood.

[17]  N. Heisterkamp,et al.  lymphoblastic leukemia , 2007 .

[18]  H. Koeffler,et al.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. , 2007, Blood.

[19]  Antonella Isacchi,et al.  Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. , 2007, Cancer research.

[20]  N. Heisterkamp,et al.  Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells , 2007, Leukemia.

[21]  M. Baccarani,et al.  Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. , 2007, Haematologica.

[22]  J. Snyder,et al.  Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function , 2007, Molecular Cancer Therapeutics.

[23]  R. Tuma.  With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model. , 2007, Journal of the National Cancer Institute.

[24]  L. Scapozza,et al.  In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. , 2006, Cancer research.

[25]  P. Manley,et al.  OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. , 2006, Blood.

[26]  B. Druker,et al.  Targeted CML therapy: controlling drug resistance, seeking cure. , 2006, Current opinion in genetics & development.

[27]  Jingxuan Pan,et al.  Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. , 2005, Cancer research.

[28]  P. D. Andrews,et al.  Aurora kinases: shining lights on the therapeutic horizon? , 2005, Oncogene.

[29]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[30]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[31]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[32]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[33]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[34]  O. Witte,et al.  The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.

[35]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[36]  J. Frasor,et al.  Therapeutic targeting in the estrogen receptor hormonal pathway. , 2004, Seminars in oncology.

[37]  Hiroshi Katayama,et al.  The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.

[38]  J. Swedlow,et al.  Mitotic mechanics: the auroras come into view. , 2003, Current opinion in cell biology.

[39]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[40]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[41]  Richard Bayliss,et al.  Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. , 2003, Molecular cell.

[42]  J. Griffin,et al.  Molecular mechanisms of transformation by the BCR-ABL oncogene. , 2003, Seminars in hematology.

[43]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[44]  H. Kantarjian,et al.  Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. , 2002, Reviews in clinical and experimental hematology.

[45]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[46]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[47]  J. Moll,et al.  Aurora kinases and their inhibitors: more than one target and one drug. , 2008, Advances in experimental medicine and biology.

[48]  N. Heisterkamp,et al.  A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl , 2004, Leukemia.

[49]  S. Hahn,et al.  Farnesyltransferase inhibitors. , 2001, Seminars in oncology.

[50]  G. Paolucci,et al.  [Treatment of acute lymphoblastic leukemia]. , 1971, Minerva pediatrica.